CSE: PHRMOTCQB: PHRRF
Contact us
Menu

Personalized medicines, 3D-⁠printed.

Powered by

​We are developing novel 3D-printed treatments for rare pediatric diseases​ and building a national network of pharmacies, hospitals, ​CDMOs, and government sites to bring​ 3D-printed medicines closer to underserved patients and national emergencies.

Partner with usInvestor presentation

CSE: PHRM · OTCQB: PHRRF

CraftTab 4-in-1 polypill, a multi-layer 3D-printed tablet, held between two fingersCraftTab assorted 3D-printed tablets in rows of different shapes, colours and layersLiquid-filled 3D-printed chewable held in a gloved handCraftMake Production Plus pharmaceutical 3D printer from Craft Health

Why 3D-printed medicines matter

Mass manufacturing leaves many patients poorly served.

Conventional manufacturing pays off only at hundreds of thousands to millions of identical units. Six needs fall outside that.

Personalized dosesOften only injections or a few fixed strengths
Children and rare diseasesAdult tablets cut at home; about 95% of rare diseases have no FDA-approved treatment
Discontinued medicinesDemand became too small for a production line
Drug shortagesMade in central plants, often overseas, far from patients
Clinical and research supplyMany strengths, in batches of a few hundred units
National emergenciesLimited stockpiles in a few standard strengths and forms
Why pharmaceutical 3D printing →
Medicines and doses, most common to least common →Units needed per product →MASS MANUFACTURINGPays only at hundreds of thousandsof identical unitsTHE LONG TAIL OF DOSESmall batches and single doses,printed on demandPeptidesRare diseasesClinical supplyCountermeasuresDiscontinuedVolume where a production line paysIllustrative

Business model

Two pillars. One platform.

The pipeline creates proprietary value. The network and partners create reach, adoption and recurring revenue, and surface new products. Each feeds the other.

We ownthe products, formulations and network
Personalized 503A products, including peptides and ketamine
FDA rare and ultra-rare disease programs
Psychedelic, discontinued and short-supply medicines
The M3DICINES™ National Network and preparedness nodes
Explore the pipeline →
We openthe platform to partners
Network placements: exclusive CraftMake™ distribution
M3DICINES™ formulation licensing and white-label products
CDMO services and research collaborations
Government readiness contracts, if awarded
Ways to partner →

Our platform

One validated recipe prints any dose.

VALIDATED1 · Formulate

Validated formulation

Proprietary blends, GRAS excipients and printed geometries.

DIGITAL RECIPEDoseset per patientFormchewableLayers2Releaseimmediate + sustained2 · Personalize

Digital recipe

Print files, parameters and methods: the manufacturing instructions for each dose.

CraftMake Production Plus pharmaceutical 3D printer3 · Print

CraftMake™ prints it

GMP-ready, heat-free and UV-free, with a digital batch record for every dose.

1%Precision
No heat, no UVRoom-temperature printing
8*Dosage forms
4Release profiles
Our platformSee CraftMake™ on M3DICINES ↗

*Oral films to be confirmed with Craft Health. 1% reflects Craft Health system specifications.

Product pipeline

Our product development focus

Our pipeline spans five areas where a precise dose, a combination or a small batch makes a medicine possible.

Explore the pipeline →
ProgramStatusNext milestone
503A personalized products
StatusLaunch planned
Next milestoneFirst launches Q4 2026; ketamine dissolvable tablet Q1 2027
Rare pediatric disease program
StatusDesignations
Next milestoneApplications October 2026 · NDA Q4 2028 (target)
Ultra-rare disease program
StatusEvaluating
Next milestoneProgram selection, 2027–2028
Psychedelic medicines
StatusPlanned
Next milestoneTrial and access supply, 2027–2028
Discontinued & short-supply medicines
StatusEvaluating
Next milestoneCandidate selection, 2027–2028

Timelines are internal estimates and forward-looking. 503A products are compounded for individual patients and are not FDA-approved.

503A personalized productsPeptides, Rx wellness and ketamine for telehealthLearn more →Rare & ultra-rare diseasesWeight-banded doses with priority review voucher potentialLearn more →Psychedelic medicinesPrecisely dosed supply for trials and special accessLearn more →Discontinued & short-supplyBringing back medicines patients still need, made closer to themLearn more →Medical countermeasuresA planned preparedness network of qualified nodesLearn more →

Partnering

Six ways to work with us.

1 · Place

Join the M3DICINES™ network

Place CraftMake™ as M3DICINES™ Network infrastructure, with validated formulations from day one.

2 · License

Formulation licensing

M3DICINES™ formulations for personalized doses, combinations and controlled release.

3 · Sell

White-label products

Pharma, peptide and nutraceutical products for telehealth and consumer-health brands.

4 · Develop

CDMO services

Formulation, clinical trial supply and small-batch manufacturing.

5 · Discover

Research collaborations

Feasibility and formulation science with pharma, universities and government.

6 · Prepare

Emergency readiness

Readiness contracts, if awarded, keep qualified nodes ready for emergencies.

Start a partnering conversationBecome a Network Partner on M3DICINES ↗

For investors

The opportunity in front of us.

US$295BPeptide therapeutics by 2033up from US$141B in 2025
US$1.2TPersonalized medicine by 2033up from US$567B in 2024
US$59BMedical countermeasures by 2030up from US$41B in 2025
Catalysts and what each unlocks
Q4 2026Network launch; first 503A productsProduct revenue begins
Q1 2027Ketamine dissolvable tablet; pre-IND meetingTelehealth sales; first ANDA payments expected
Next 12 monthsUp to 50 placements; preparedness demoProductive nodes and recurring revenue
2027–28Licences, readiness contracts, new programsUltra-rare, psychedelic, discontinued and short-supply
Q4 2028Rare pediatric NDA (target)Path to orphan exclusivity
BeyondFirst FDA approval of a PharmaTher printed medicinePotential priority review voucher

Market sizes are third-party estimates of total markets, not PharmaTher revenue. Targets and timelines are internal estimates and forward-looking. Forward-looking statements

Latest news

All news →
October 7, 2026
PharmaTher Launches M3DICINES™ National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
Read release →
October 5, 2026
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D™ as M3DICINES™
Read release →
October 1, 2026
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake™ Pharmaceutical 3D Printing Platform
Read release →